Global R&D Pipeline
My Favorite
Hot Targets:
TROP2
Back
Total number of drugs
184
Phase II and later clinical stages
4.9%
Involving companies
246
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DAC-002 | DAC-002 | Antibody drug conjugate (ADC) | Neoplasms Respiratory Diseases Skin and Musculoskeletal Diseases | Trop-2 modulators | Hangzhou DAC Biotechnology Co., Ltd. | Shanghai Junshi Biosciences Co., Ltd. Hangzhou DAC Biotechnology Co., Ltd. | Phase 1/2 | Phase 1/2 | - | - | - | - | - | Disulfide cleavable | Tub196 | - | DAC-002 | - | - | detail > | |
| Anti-Trop2 Universal CAR-NK cell(Henan Cancer Hospital) | Anti-Trop2 Universal CAR-NK cell(Henan Cancer Hospital) | CAR-NK | Neoplasms Respiratory Diseases | Trop-2 modulators Immunologic cytotoxicity Natural killer cell replacements | Henan Cancer Hospital | Henan Cancer Hospital | Phase 1/2 | Phase 1 | - | - | - | - | - | - | - | - | Anti-Trop2 Universal CAR-NK cell(Henan Cancer Hospital) | - | - | detail > | |
| BSI-992 | BSI-992 | Antibody drug conjugate (ADC) | Neoplasms Digestive System Disorders Respiratory Diseases | TOP1 inhibitors Trop-2 inhibitors | Biosion, Inc. | Biosion, Inc. OBI Pharma, Inc. Biosion Usa, Inc. | Phase 1/2 | IND Application | - | - | - | Orphan Drug（United States） | BSI-04702 | - | Exatecan | 4 | BSI-992 | - | - | detail > | |
| LCB-84 | LCB-84 | Antibody drug conjugate (ADC) | Neoplasms Digestive System Disorders Endocrinology and Metabolic Disease Hemic and Lymphatic Diseases Respiratory Diseases Skin and Musculoskeletal Diseases | Trop-2 inhibitors Tubulin inhibitors | Mediterranea Theranostic Srl | LigaChem Biosciences, Inc. Johnson & Johnson | Phase 1/2 | - | - | - | - | - | - | β-glucuronide | MMAE | - | LCB-84 | - | - | detail > | |
| VBC-103 | VBC-103 | Antibody drug conjugate (ADC) | Neoplasms Skin and Musculoskeletal Diseases | Trop-2 inhibitors nectin-4 inhibitors | Shanghai Chengfan Pharmaceutical Co. Ltd. | Shanghai Chengfan Pharmaceutical Co. Ltd. Avenzo Therapeutics, Inc. | Phase 1/2 | IND Application | - | - | - | - | - | - | - | - | VBC-103 | - | - | detail > | |
| GQ-1010 | GQ-1010 | Antibody drug conjugate (ADC) | Neoplasms Respiratory Diseases Skin and Musculoskeletal Diseases | Trop-2 inhibitors | GeneQuantum Healthcare (Suzhou) Co. Ltd. | GeneQuantum Healthcare (Suzhou) Co. Ltd. Biohaven Ltd. Taili Biotechnology Shanghai Co Ltd. Pyramid Biosciences, Inc. Biohaven Therapeutics Ltd. | Phase 1/2 | Phase 1/2 | - | - | - | - | - | - | - | - | GQ-1010 | - | - | detail > | |
| HS-20105 | HS-20105 | Antibody drug conjugate (ADC) | Neoplasms | Trop-2 modulators | Changzhou Hansoh Pharmaceutical Co., Ltd. Shanghai Hansoh Biomedical Co. Ltd. | Shanghai Hansoh Biomedical Co. Ltd. Changzhou Hansoh Pharmaceutical Co., Ltd. | Phase 1/2 | Phase 1 | - | - | - | - | - | Cleavable linker | - | - | HS-20105 | - | - | detail > | |
| Datopotamab Deruxtecan | Datopotamab Deruxtecan | Antibody drug conjugate (ADC) | Neoplasms Respiratory Diseases Skin and Musculoskeletal Diseases Nervous System Diseases Digestive System Disorders Endocrinology and Metabolic Disease Urogenital Diseases | TOP1 inhibitors Trop-2 inhibitors | Daiichi Sankyo Co., Ltd. | Baxter Oncology GmbH Daiichi Sankyo, Inc. AstraZeneca Investment (China) Co. Ltd. Daiichi Sankyo Co., Ltd. AstraZeneca PLC Daiichi Sankyo (China) Holdings Co., Ltd. Merck Sharp & Dohme Corp. Merck Sharp & Dohme LLC Daiichi Sankyo Propharma Co., Ltd. AstraZeneca AB Daiichi Sankyo Europe GmbH Institut Gustave Roussy EURL AstraZeneca Canada, Inc. AstraZeneca Pty Ltd. Yale University | Approved | Approved | United States China European Union Japan Canada Australia Iceland Liechtenstein Norway | 2024-12-27 | 2025-08-19 | Accelerated Approval（United States） Breakthrough Therapy（United States） Priority Review（United States） | Datopotamab | MC-GGFG | DXd | 4 | Datopotamab Deruxtecan | IgG1 - kappa | cysteinyl | detail > | |
| BIO-106(BiOneCure) | BIO-106(BiOneCure) | Antibody drug conjugate (ADC) | Neoplasms | Trop-2 inhibitors Tubulin inhibitors | BiOneCure Therapeutics, Inc. | BiOneCure Therapeutics, Inc. | Phase 1/2 | - | - | - | - | - | - | Non-cleavable linker | Maytansinoid | - | BIO-106(BiOneCure) | - | - | detail > | |
| Sacituzumab tirumotecan | Sacituzumab tirumotecan | Antibody drug conjugate (ADC) | Neoplasms Skin and Musculoskeletal Diseases Respiratory Diseases Digestive System Disorders Urogenital Diseases Other Diseases Endocrinology and Metabolic Disease | TOP1 inhibitors Trop-2 inhibitors | Sichuan Kelun Pharmaceutical Co., Ltd. | MSD R&D (China) Co. Ltd. Merck Sharp & Dohme LLC KLUS Pharma, Inc. Sichuan Kelun Botai Biomedicine Co., Ltd. Sichuan Kelun Pharmacy Institute Co., Ltd. Merck & Co., Inc. | Approved | Approved | China | 2024-11-22 | 2024-11-22 | Breakthrough Therapy（China） Breakthrough Therapy（United States） Priority Review（China） Conditional marketing approval（China） | Sacituzumab | Sulfonyl Pyrimidine-CL2A-Carbonate | KL610023 | 7.4 | Sacituzumab tirumotecan | IgG1 - kappa | cysteinyl | detail > |
Total 184 data
1
2
3
4
5
6
...
18
19
